• Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. 30 studies from 24 independent teams in 12 different countries show statistically significant improvements in isolation (17 for the most serious outcome).
• Meta analysis using the most serious outcome reported shows 30% [21‑38%] improvement. Results are better for Randomized Controlled Trials, similar after exclusions, and similar for peer-reviewed studies.
• Results are robust — in exclusion sensitivity analysis 24 of 49 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
• This analysis combines the results of several different antiandrogens. Results for individual treatments may vary.
• No treatment, vaccine, or intervention is 100% effective and available. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective. Only 18% of antiandrogen studies show zero events with treatment.
• All data to reproduce this paper and sources are in the appendix. Other meta analyses for antiandrogen can be found in [Cheema, Kotani], showing significant improvements for mortality, hospitalization, recovery, and progression.
Percentage improvement with antiandrogen (more) | All studies | Early treatment | Late treatment | Studies | Patients | Authors |
All studies | 30% [21‑38%]**** | 44% [31‑55%]**** | 64% [46‑75%]**** | 49 | 119,838 | 533 |
Randomized Controlled TrialsRCTs | 58% [37‑73%]**** | 64% [26‑82%]** | 58% [32‑74%]*** | 18 | 2,942 | 220 |
Mortality | 38% [22‑51%]**** | 39% [29‑48%]**** | 63% [45‑76%]**** | 33 | 113,013 | 370 |
HospitalizationHosp. | 30% [9‑47%]** | 81% [46‑93%]** | 21% [-10‑43%] | 15 | 8,854 | 218 |
RCT mortality | 63% [46‑75%]**** | 71% [-75‑95%] | 62% [41‑75%]**** | 14 | 2,630 | 161 |
Covid Analysis et al., Jun 2023, preprint, 1 author.